Varespladib methyl API Manufacturers

compare suppliers & get competitive offers

teaser-1024x654-1
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Varespladib methyl is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Varespladib methyl or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Varespladib methyl API 172733-08-3?

Description:
Here you will find a list of producers, manufacturers and distributors of Varespladib methyl. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Varespladib methyl 
Synonyms:
Varespladib methyl ester  
Cas Number:
172733-08-3 
DrugBank number:
DB05737 
Unique Ingredient Identifier:
0NB98NBX3D

General Description:

Varespladib methyl, identified by CAS number 172733-08-3, is a notable compound with significant therapeutic applications. Varespladib methyl has been investigated for the treatment of Acute Coronary Syndrome. Studies showed that Varespladib methyl treatment resulted in significant positive changes on lipoproteins and inflammation.

Indications:

This drug is primarily indicated for: Investigated for use/treatment in atherosclerosis and coronary artery disease. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Mechanism of Action:

Varespladib methyl functions by: A–002 is an orally administered‚ potent inhibitor of secretory phospholipase spla2(spla2)‚ including groups IIA‚ V‚ and X. Atherosclerosis is a disease of the arteries that results from inflammation and the build-up of plaque under the lining of the blood vessel. This build-up can cause vascular swelling and eventual rupture. spla2 levels have been shown to be elevated in patients with both stable and unstable coronary artery disease. Higher levels of the enzyme have been shown to predict an increased risk for future cardiovascular events such as heart attacks and stroke. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Classification:

Varespladib methyl belongs to the class of organic compounds known as phenoxyacetic acid derivatives. These are compounds containing an anisole where the methane group is linked to an acetic acid or a derivative, classified under the direct parent group Phenoxyacetic acid derivatives. This compound is a part of the Organic compounds, falling under the Benzenoids superclass, and categorized within the Benzene and substituted derivatives class, specifically within the Phenoxyacetic acid derivatives subclass.

Categories:

Varespladib methyl is categorized under the following therapeutic classes: Acids, Acyclic, Enzyme Inhibitors, Fatty Acids, Fatty Acids, Volatile, Heterocyclic Compounds, Fused-Ring, Lipids, Phospholipase A2 Inhibitors. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Varespladib methyl is a type of Dental and Oral Agents


Dental and oral agents belong to the pharmaceutical API category, playing a crucial role in oral health care. These agents are specifically designed to address various dental and oral conditions, ranging from tooth decay and gum diseases to oral infections and inflammation.

One of the primary types of dental and oral agents is antimicrobial APIs. These active pharmaceutical ingredients are known for their ability to inhibit the growth of bacteria and fungi in the oral cavity, helping to prevent and treat infections. Common antimicrobial APIs used in dental and oral care include chlorhexidine, cetylpyridinium chloride, and triclosan.

Another important category is analgesic APIs, which provide pain relief in dental and oral procedures. These agents work by blocking pain signals and reducing inflammation. Popular analgesic APIs in dental care include lidocaine, benzocaine, and ibuprofen.

Fluoride APIs are widely used in dental products to strengthen tooth enamel and prevent tooth decay. These APIs aid in remineralization, making teeth more resistant to acid attacks from bacteria and sugary foods.

Furthermore, there are APIs specifically formulated for treating specific oral conditions such as dry mouth or halitosis. These agents help restore moisture in the mouth and neutralize odor-causing compounds.

Dental and oral agents are typically formulated into various dosage forms, including mouthwashes, toothpaste, gels, and oral sprays. These formulations ensure convenient and effective delivery of the APIs to the affected areas in the oral cavity.

In summary, dental and oral agents are a vital component of oral health care, offering antimicrobial, analgesic, remineralizing, and specific therapeutic benefits. Incorporating these pharmaceutical APIs into dental products helps individuals maintain optimal oral health and prevent dental problems.